Crinetics Pharmaceuticals
NASDAQ · CRNX·San Diego, CA·Mid-cap·Phase 3
Clinical-stage pharma developing oral small molecules for endocrine diseases. Lead asset paltusotine is a once-daily oral SST2 agonist with positive Phase 3 PATHFNDR data in acromegaly and Phase 3 in carcinoid syndrome. Pipeline includes atumelnant (ACTH antagonist) for Cushing's.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Crinetics Corporate Presentation February 2026 | Corporate overview | February 15, 2026 | 45 |